Short Interest in Aptose Biosciences Inc. (NASDAQ:APTO) Grows By 1,012.9%

Aptose Biosciences Inc. (NASDAQ:APTOGet Free Report) (TSE:APS) saw a large increase in short interest in January. As of January 15th, there was short interest totalling 2,090,000 shares, an increase of 1,012.9% from the December 31st total of 187,800 shares. Based on an average daily trading volume, of 6,360,000 shares, the days-to-cover ratio is currently 0.3 days. Currently, 3.7% of the shares of the stock are sold short.

Institutional Investors Weigh In On Aptose Biosciences

An institutional investor recently raised its position in Aptose Biosciences stock. Sigma Planning Corp lifted its holdings in Aptose Biosciences Inc. (NASDAQ:APTOFree Report) (TSE:APS) by 71.3% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 401,750 shares of the biotechnology company’s stock after acquiring an additional 167,282 shares during the quarter. Sigma Planning Corp owned approximately 2.22% of Aptose Biosciences worth $165,000 at the end of the most recent reporting period. 26.62% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

APTO has been the topic of several recent research reports. HC Wainwright reiterated a “buy” rating and set a $2.00 target price on shares of Aptose Biosciences in a research report on Friday, January 10th. StockNews.com started coverage on Aptose Biosciences in a report on Friday, January 24th. They set a “hold” rating on the stock.

Get Our Latest Research Report on APTO

Aptose Biosciences Stock Performance

Shares of NASDAQ APTO opened at $0.17 on Thursday. Aptose Biosciences has a 52-week low of $0.13 and a 52-week high of $2.20. The business has a fifty day moving average of $0.21 and a two-hundred day moving average of $0.36. The stock has a market cap of $10.39 million, a PE ratio of -0.06 and a beta of 0.87.

About Aptose Biosciences

(Get Free Report)

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.

Featured Stories

Receive News & Ratings for Aptose Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.